The Technical Analyst
GeoVax Labs, Inc. [GOVX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
GeoVax Labs, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.35% $1.540
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.55 mill |
| EPS: | -14.29 |
| P/E: | -0.110 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 2.31 mill |
| Avg Daily Volume: | 0.0430 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.110 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.110 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.55 (130.56%) $2.01 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.344 - 1.736 ( +/- 12.73%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-22 | Dodd David A | Buy | 8 209 | Common Stock |
| 2024-02-21 | Dodd David A | Buy | 520 | Common Stock |
| 2024-02-07 | Reynolds Mark | Buy | 2 000 | Common Stock |
| 2023-12-22 | Mckee Kelly T. Jr. | Buy | 6 944 | Common Stock |
| 2023-09-25 | Mckee Kelly T. Jr. | Buy | 9 653 | Common Stock |
| INSIDER POWER |
|---|
| 99.71 |
| Last 95 transactions |
| Buy: 15 241 679 | Sell: 50 000 |
Forecast:
16:00 - $1.540
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.540
Forecast 2: 16:00 - $1.540
Forecast 3: 16:00 - $1.540
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.540 (-4.35% ) |
| Volume | 0.0319 mill |
| Avg. Vol. | 0.0430 mill |
| % of Avg. Vol | 74.13 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GOVX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Latest Press Releases
2024-04-04 12:30:00 - Press Release
Geovax Presents Data On Geo-cm04s1, A Next Generation Covid-19 Vaccine
Presentation made during the 24th annual world vaccine congress atlanta, ga, april 04, 2024 (globe newswire) -- via newmediawire -- geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its chief scientific officer, mark newman, phd, presented data on geo-cm04s1, the company's next-generation covid-19 vaccine candidate, during the 24th annual world vaccine congress in washington, dc. during his presentation, titled “vaccine induction of broadly-specific antibody and t cell responses to combat sars-cov-2 variation”, dr. newman described geovax's development program for geo-cm04s1.
2024-03-28 09:00:00 - Press Release
Geovax To Present Data On Geo-cm04s1, A Next Generation Covid-19 Vaccine, At The World Vaccine Congress
Atlanta, ga, march 28, 2024 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its chief scientific officer, mark newman, phd, will present data on geo-cm04s1, the company's next-generation covid-19 vaccine candidate, during the upcoming 24th annual world vaccine congress taking place in washington, dc on april 1-4, 2024.
2024-03-12 09:00:00 - Press Release
Geovax To Present At The 36th Annual Roth Conference
Atlanta, ga, march 12, 2024 (globe newswire) -- via newmediawire -- geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its chairman and ceo, david dodd, will present at the 36th annual roth conference, taking place in dana point, ca on march 17-19, 2024.
2024-03-06 09:00:00 - Press Release
Geovax Achieves Milestone In Transition To Commercially Validated Manufacturing System
Manufacturing process for phase 3 and commercial production being developed for geovax mva-based vaccines atlanta, ga, march 06, 2024 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a significant milestone toward implementation of a validated chicken embryonic fibroblast (cef) based production system for the company's mva-based vaccines, with the release of its first lot of geo-cm04s1 (next-generation covid-19 vaccine) produced with a commercial manufacturing platform. this milestone marks the successful completion of the transfer and scale-up of manufacturing from the research-focused center for biomedicine & genetics at city of hope (duarte, ca) to the experienced cdmo abl europe (a subsidiary of oxford biomedica), the company's cgmp (current good manufacturing procedures) manufacturing partner.
2024-02-29 16:00:00 - Press Release
Geovax Reports 2023 Year-end Financial Results And Provides Business Update
Progress across the pipeline in multiple clinical trials, including phase 2 program of geo-cm04s1, next-generation covid-19 vaccine, and multicenter phase 1/2 study of gedeptin ® , targeting advanced head and neck cancer
Latest News
2024-03-28 09:00:00 - GlobeNewsWire
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024.
2024-03-12 09:00:00 - GlobeNewsWire
GeoVax to Present at the 36th Annual Roth Conference
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference, taking place in Dana Point, CA on March 17-19, 2024.
2024-03-01 02:34:02 - Seeking Alpha
GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
2024-02-22 09:00:00 - GlobeNewsWire
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report 2023 financial results on Thursday, February 29, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m.
2024-02-19 09:00:00 - GlobeNewsWire
GeoVax to Present at the 2024 BIO CEO & Investor Conference
ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.
2023-12-27 09:00:00 - GlobeNewsWire
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will present at the Biotech Showcase coinciding with the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, January 8-11, 2024.
2023-11-08 21:26:03 - Seeking Alpha
GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript
2023-09-12 09:00:00 - GlobeNewsWire
GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference
Updates Presented for Gedeptin® and GEO-CM04S1 Phase 2 Clinical Trials ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, presented a company overview during the H.C.
2023-08-31 09:00:00 - GlobeNewsWire
GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Company to Provide Updates on Multiple Phase 2 Clinical Trials for GEO-CM04S1 and Gedeptin® ATLANTA, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will present a company overview and host investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York City.
2023-08-29 09:00:00 - GlobeNewsWire
GeoVax to Present at the Emerging Growth Conference on September 6, 2023
Company to Provide Updates on Multiple Phase 2 Clinical Trials for its Next-Generation COVID-19 Vaccine and Cancer Immunotherapy Programs